linjc16/ctgov huggingface dataset:
Revealing Engagement Patterns Among Endometrial Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The study intends to investigate the personal experiences of endometrial cancer patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal. The data collected from this study will help improve future outcomes for all endometrial cancer patients as well as those in under-represented demographic groups.

Official Title
-----------------
A Journey Endometrial Cancer Clinical Trials - Revealing Engagement Patterns Among Individuals Affected by Endometrial Cancer

Conditions
-----------------
Endometrial Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with endometrial cancer Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: Refusal of consent Women of childbearing potential without a negative pregnancy test; or women who are lactating. Any serious and/or unstable pre-existing medical disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in an endometrial cancer clinical research |  | 3 months | 
| Rate of patients who remain in an endometrial cancer clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endometrial cancer
COVID-19 Associated With Psoriasis

Study Overview
=================
Brief Summary
-----------------
A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Detailed Description
-----------------
Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

Official Title
-----------------
Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis

Conditions
-----------------
Psoriasis Patients, COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria ---- No age limit, both male and female are accepted; Psoriasis patients registered in the database; Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided. Exclusion criteria ---- Patients are thought having conditions which are not appropriated for attending this clinical trial.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection | The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis. | March 15,2023 to May 30,2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection | Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection | March 15,2023 to May 30,2023 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psoriasis, covid-19
The Eye in Orbit: UCF Adaption

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to understand the impact of space travel on the eyes. Space flight impacts numerous aspects of ocular anatomy and physiology. Current hypotheses are based on pressure changes within and around the optic nerve. Retinal and choroid blood drainage may be affected by microgravity associated cerebrospinal fluid pressure changes. Recently, a new imaging modality, Optical Coherence Tomography Angiography (OCTA), has been able to reveal micro vascular changes in the retina and choroid. To date, no microgravity ocular imaging tests have been published using OCTA. In this study the researchers aim to describe microgravity circadian choroidal and retinal vasculature using multimodal imaging including OCTA to better understand space associated ocular changes.

Official Title
-----------------
The Eye in Orbit- Analysis of the Anatomical and Functional Ocular Changes Related to Space Flights: UCF Adaptation.

Conditions
-----------------
Spaceflight Associated Neuro-Ocular Syndrome, SANS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - astronauts in the AX1/Rakia mission, which was scheduled for space flight in late March 2022. Exclusion Criteria: adults unable to consent individuals who are not yet adults (infants, children, teenagers) - pregnant women prisoners.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To examine early changes in ocular physiology following exposure to microgravity and asses these changes as risk factor for Spaceflight Associated Neuro-Ocular Syndrome (SANS). |  | 4 months | 
| Asses early changes in ocular physiology as risk factor for Spaceflight Associated Neuro-Ocular Syndrome (SANS). |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SANS, Spaceflight Associated Neuro-Ocular Syndrome, Optical Coherence Tomography Angiography, OCTA, Space, Astronaut
Study of Nasal Mucosa Histopathological Changes in Chronic Hypersensitivity Pneumonitis

Study Overview
=================
Brief Summary
-----------------
Background:Hypersensitivity pneumonitis (HP) is an interstitial lung disease that develops after inhalation of organic or inorganic antigens in susceptible individuals. The nasal mucosa is constantly exposed to these antigens that can irritate the respiratory mucosa. Objectives: to assess the burden of sinonasal symptoms in HP patients and to evaluate the nasal histopathology in those patients.

Official Title
-----------------
Study of Nasal Mucosa Histopathological Changes in Patients With Chronic Hypersensitivity Pneumonitis

Conditions
-----------------
Hypersensitivity Pneumonitis, Nasal Mucosal Disorder

Intervention / Treatment
-----------------
* Procedure: nasal endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients with clinical and radiological features of HP Exclusion Criteria: respiratory failure patients on anticoagulants

Ages Eligible for Study
-----------------
Minimum Age: 29 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: chronic HP patients<br> | Procedure: nasal endoscopy<br>* nasal endoscopy and mucosal biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients with HP developed nasal mucosa granuloma and lymphocytic infiltrations as detected by nasal endoscopy | nasal endoscopy and nasal mucosa biopsy was done for all patients to measure the % of patients with nasal granuloma and lymphocytic infiltrations | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypersensitivity pneumonitis, nasal mucosa histopaholgical changes
Non Obstructive Versus Obstructive Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to study the non obstructive type of ischemic heart disease by identifying unique clinical features , frequency and age group .in patient admitted in coronary care unit , suffered from angina or heart attack. . The main question[s] it aims to answer are: how it different from classical type of ischemic heart disease ( obstructive coronary artery disease) what is frequency and age prevalence of these patient Participants evaluated by history , clinical examination, serum troponin and coronary angiography.

Official Title
-----------------
Non Obstructive Versus Obstructive Coronary Artery Disease Documented by Coronary Angiography; Prevalence & Diagnostic Features in a Single Center Experience : A Prospective Cross Sectional Study

Conditions
-----------------
Non-Obstructive Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: CORONARY ANGIOGRAPHY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with IHD ( MI, unstable angina ,chronic stable angina) >18 years of age patients undergoing CAG for emergency or elective situations. Exclusion Criteria: Patients who were hemodynamically unstable. patients with incomplete data patients with clinical features of pericarditis or others of non cardiac origin chest pain .

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 81 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non obstructive versus obstructive coronary artery disease documented by coronary angiography; prevalence & diagnostic features in a single center experience : A prospective cross sectional study | analysis of diagnostic features and frequency of non obstructive artery disease in comparison to obstructive artery disease | BASELINE |
Correlation of Children's Electronic Screen Time Exposure and Dental Anxiety and Behavior

Study Overview
=================
Brief Summary
-----------------
This study aims to detect the correlation between children's electronic screen time exposure and dental anxiety and behavior in a group of Egyptian children

Official Title
-----------------
Correlation of Children's Electronic Screen Time Exposure and Dental Anxiety and Behavior in a Group of Egyptian Children

Conditions
-----------------
Children's Screen Exposure

Intervention / Treatment
-----------------
* Behavioral: dental anxiety


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children aged 6-to-8-years old First dental visit Both genders Exclusion Criteria: Children with Mental or neurological disorders. Children with Systemic disorders. Children who use medications that could interfere with the central nervous system Children with previous hospitalization

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: dental anxiety|Evaluate dental anxiety in children and its relation with screen time exposure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Child dental anxiety | Abeer children dental anxiety SCALE,Questionnaire | through study completion, an average of 1 year | 
| Assessment of the child's behavior during the dental visit | Frankl Behavioral Rating Scale,Questionnaire | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exposure to electronic screens | Questionnaire | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dental anxiety
HU007 in Patients With Dry Eye Syndrome

Study Overview
=================
Brief Summary
-----------------
A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

Official Title
-----------------
A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

Conditions
-----------------
Dry Eye Disease

Intervention / Treatment
-----------------
* Drug: HU007
* Drug: Restasis
* Drug: Moisview Eye drop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Age over 19 Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 in at least one of both eyes Volunteer who have had more than one symptom of dry eye disease for at least 3 month before screening visit. Exclusion Criteria: The patients with clinically significant ocular disorders affected the test result Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c>9% Wearing contact lenses within 72 hr of screening visit Pregnancy or Breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HU007<br>Cyclosporine 0.02%, trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks | Drug: HU007<br>* cyclosporine 0.02%, trehalose 3%<br>|
| Active Comparator: Restasis<br>Cyclosporine 0.05% 1 drop b.i.d at 12hr interval for 12 weeks | Drug: Restasis<br>* cyclosporine 0.05%<br>|
| Active Comparator: Moisview<br>trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks | Drug: Moisview Eye drop<br>* trehalose 3%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from Baseline in Corneal staining(Oxford grading) score | change from Baseline in Corneal staining(Oxford grading) score - Oxford grading:0(Absent) to 5(Severe) | Week12 |
Determining the Mechanisms of Loss of CAR T Cell Persistence

Study Overview
=================
Brief Summary
-----------------
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Official Title
-----------------
Determining the Mechanisms of Loss of CAR T Cell Persistence

Conditions
-----------------
Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, in Relapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel) Written informed consent Exclusion Criteria: Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

Ages Eligible for Study
-----------------
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to circulating CAR-T cell loss | CAR-T persistence will be measured in the central lab from blood samples. | Through study completion, until the last patient reaches 1 year post-infusion |
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study is being performed to compare the systemic pharmacokinetic profiles of T4032 and Lumigan 0.01% given that T4032 has a different formulation (in terms of excipients) from the reference product.

Official Title
-----------------
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: Bimatoprost Ophthalmic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent signed and dated Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study Participants with no ocular symptoms Exclusion Criteria: History of ocular trauma, infection, or inflammation within the last 3 months Presence of an ocular pathology such as blepharitis, conjunctivitis, uveitis, or any other ocular infection or inflammation IOP <10 mmHg or >21 mmHg

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: T4032<br> | Drug: Bimatoprost Ophthalmic<br>* eyedrops<br>|
| Active Comparator: Lumigan<br> | Drug: Bimatoprost Ophthalmic<br>* eyedrops<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma concentrations of bimatoprost and bimatoprost free acid at each timepoint (in ng/mL) |  | at 2 timepoint : Baseline and week 2 | 
| Ocular and systemic adverse events |  | up to week 2 |
Outcome of GI Cancer in NCKUH

Study Overview
=================
Brief Summary
-----------------
Alimentary tract cancer patients treated at National Cheng Kung University Hospital during 2013/01/01 to 2020/12/31 were reviewed.

Detailed Description
-----------------
We would like to explore the treatment strategy and clinical outcome of alimentary tract cancer in National Cheng Kung University Hospital. The result could help physician to further realize the real world practice of cancer treatment in Taiwan and might also help clinician to optimize the diagnosis and treatment strategy in alimentary tract cancer patients. Alimentary tract cancer patients treated at National Cheng Kung University Hospital during 2013/01/01 to 2020/12/31.

Official Title
-----------------
Explore the Diagnosis and Treatment Outcome of Alimentary Tract Cancer in National Cheng Kung University Hospital

Conditions
-----------------
Collection of Real-world Data in a Single Institute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with pancreatic cancer treated at National Cheng Kung University Hospital during 2013/01/01 to 2020/12/31 Exclusion Criteria: No treatment or refuse treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Resectable<br>Patients with resectable pancreatic cancer | |
| Borderline resectable<br>Patients with borderline resectable pancreatic cancer | |
| Locally advanced<br>Patients with locally advanced unresectable pancreatic cancer | |
| Metastatic<br>Patients with metastatic pancreatic cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | Overall survival of patient received study treatment | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) | Progression-free survival of patient received study treatment | 10 years |